Boér K. Fulvestrant in advanced breast cancer: evidence to date and place in therapy. *Therapeutic Advances in Medical Oncology* 2017; 9: 465-479. DOI: 10.1177/1758834017711097

This article, published in the July Issue of Therapeutic Advances in Medical Oncology, has the following corrections: Table 1 (page 469):Regarding the CONFIRM trial, the 'Primary endpoint' was incorrectly listed as 'TTP' (time to progression), and should have been listed as 'PFS' (progression-free survival).Regarding the Paloma-3 trial, the data in the 'CBR or ORR (%)' column were incorrectly listed as '24.6 versus 10.9 (CBR) p = 0.0012', and should have been listed as '34.0 versus 19.0 (CBR), p \< 0.001'.Regarding the PrECOG 0102 trial, the number of participants ('n') was incorrectly listed as '131', and should have been listed as '130'.On page 473 (left-hand column, first paragraph), the percentages listed for the most common grade 3 or 4 adverse events were taken from Cristofanilli *et al.* (reference 35 in the article reference list). This was not clear in the article.On page 473 (left-hand column, third paragraph), the number of participants in the PrECOG 0102 trial was incorrectly listed as '131', and should have been listed as '130'.On page 473 (right-hand column, first paragraph), the following text was incorrect: "The combination was associated with greater toxicity; the most frequent grade 3 adverse events were stomatitis (9%), pneumonitis (6%), fatigue (5%), and hyperglycaemia (6%)." This text should instead have read "Grade 3/4 AEs were more common in the everolimus arm, including hyperglycemia (16%/0% vs 0%), stomatitis (11%/0% vs 0%), hypertriglyceridemia (9%/2% vs 0%), lymphopenia (9%/0% vs 0%), and pneumonitis (6%/2% vs 0%)."On page 474 (right-hand column, first paragraph), the p-value for PFS for the HER2+ve subgroup was incorrectly listed as 'p = 5.53' and should have been listed as 'p = 0.53'.

The author and the editors would like to apologise for these errors.
